Macrophage Checkpoint Nanoimmunotherapy for Ovarian Cancer
Author Information
Author(s): VandenHeuvel Sabrina N., Chau Eric, Mohapatra Arpita, Dabbiru Sameera, Roy Sanjana, O’Connell Cailin, Kamat Aparna, Godin Biana, Raghavan Shreya A.
Primary Institution: Texas A&M University
Hypothesis
Can lipid-based nanoparticles deliver siRNA to macrophages to disrupt CD47-SIRPα signaling in metastatic ovarian cancer?
Conclusion
The study demonstrates that using lipid nanoparticles to deliver siRNA can reduce SIRPα expression in macrophages, enhancing the effectiveness of chemotherapy against ovarian cancer.
Supporting Evidence
- Macrophages in ovarian cancer spheroids increased chemoresistance and invasion.
- siSIRPα LNPs significantly reduced SIRPα gene and protein expressions.
- Disrupting CD47-SIRPα interactions sensitized ovarian cancer/macrophage heterospheroids to platinum chemotherapy.
Takeaway
This research shows that tiny particles can help deliver medicine to immune cells in cancer, making the cancer easier to treat.
Methodology
The study used lipid nanoparticles to deliver siRNA targeting SIRPα in macrophages within engineered tumor spheroids to assess effects on ovarian cancer progression.
Limitations
The study primarily focuses on in vitro models, which may not fully replicate in vivo conditions.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website